Аннотация:The fibrotic interstitial lung diseases (ILDs) encompass a heterogenous group of conditions affecting the lung parenchyma, resulting in progressive, irreversible scarring. While prognosis varies between conditions, they commonly have a significant adverse impact both on health-related quality of life (HRQoL) and on survival. For idiopathic pulmonary fibrosis (IPF), the most common and fatal ILD, antifibrotic therapies (nintedanib [1] and pirfenidone [2]) have been shown to slow rate of progression, but the disease remains incurable. Management of all fibrotic ILDs therefore requires symptomatic and supportive care as well as interventions aimed at modifying the disease course [3]. The AmbOx trial provides RCT evidence for ambulatory oxygen therapy improving HRQoL in patients with fibrotic ILD
Ключевые слова:Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Sarcoidosis and Beryllium Toxicity Research, Respiratory and Cough-Related Research
